Drugs / V118C
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07300267 | Jan 2026 → Oct 2028 expected | pneumococcal infection | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06611033 | Sep 2024 → Jan 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V118C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06611033 ↗ |
| Modality | Vaccine | “V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria.” NCT07300267 ↗ |
| Route | Intramuscular | “IM administration of V118C” NCT07300267 ↗ |